The Pharma Data

JUNE 25, 2025

scheduled for 2026 to 2030. This vaccine rollout, made possible through partnerships among GSK, Bharat Biotech, PATH, WHO, MedAccess, and country governments, marks a turning point in the fight against malaria—a disease that continues to claim hundreds of thousands of lives each year, especially among children under the age of five.

Vaccine 52

Vaccine Production Hospitals Disease 52

The Pharma Data

NOVEMBER 12, 2020

Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 sets out global targets and actions to align and re-focus the work of countries, partners and stakeholders during. and economic consequences imposed by these diseases. ”. 2030 road map targets. “The.

Disease 52

Disease Government Treatment 52

Drug Target Review

SEPTEMBER 21, 2023

The findings supported the possibility put forward by Cotton et al (2016) concerning the chance of repurposing these drugs for adulticidal treatment. The available treatment for that is minor surgery -to remove the nodules. Need for adulticidal drugs More than 99 percent of countries worldwide has been affected by this disease.

Drugs 105

Drugs Treatment Disease Research 105

The Pharma Data

MAY 31, 2022

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

The Pharma Data

NOVEMBER 15, 2020

Diadem’s Minimally Invasive Blood-Based AlzoSure® Prognostic Test for Early Alzheimer’s Disease Selected for Potential to Help Transform Management of this Devastating Global Disorder. “Alzheimer’s disease and other dementias afflict more than 50 million people worldwide. . MILAN , Nov.

Disease 40

Disease Treatment Production Clinical Trials 40

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. CRISPR engineering in organoids for gene repair and disease modelling.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). This Refinement Therapeutic Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous specific for the treatment of Alzheimer’s trouble with the prospect for at- home administration.”

Disease 52

Disease FDA Therapies Trials 52

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). “This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.

Therapies 52

Therapies Disease FDA Trials 52

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

NOVEMBER 2, 2020

million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO). billion cumulative treatments to more than 923 million people since 2000. Setting sights on 2030. In 2019, 538.1

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

FEBRUARY 21, 2022

Such success stories are encouraging and help us to eliminate more diseases in our Region.”. The disease. Trachoma is a devastating eye disease caused by infection with the bacterium Chlamydia trachomatis. To eliminate trachoma, WHO recommends the SAFE strategy 2 to achieve elimination of trachoma as a public health problem.

Disease 52

Disease Treatment International Drugs 52

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

NOVEMBER 1, 2020

MS is an autoimmune, inflammatory disease of the central nervous system. billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. The trial is expected to enroll 160 patients. billion in 2018, and it is expected to be up to US$48.9

Clinical Trials 40

Clinical Trials Trials FDA Treatment 40

New Drug Approvals

JANUARY 31, 2024

In addition to hyperlipidemia and type 2 diabetes, a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) has occurred. The present invention addresses these needs for new treatment methods, compounds, and pharmaceutical compositions. Current drugs that treat hyperlipidemia (e.g., Skjaeret, et al.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis.

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

JULY 29, 2021

P-tau217 in blood showed promise as additional biomarker of efficacy- Donanemab treatment led to 24% lowering of P-tau217 from baseline. Donanemab is also being studied in the ongoing Phase 3 TRAILBLAZER-ALZ 2 study in early, symptomatic Alzheimer’s disease patients. vice president of pain and neurodegeneration, Lilly.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

Vial

APRIL 18, 2024

Yet, hereditary and age-related retinal diseases present challenges, often leading to progressive vision loss and potential blindness. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Drug Target Review

OCTOBER 1, 2024

The possibility of using new technologies to build new, more effective and less toxic therapies has opened new horizons for the treatment of cancer. Moreover, increasing treatment complexity will require more sophisticated scientific exchange. Oncology has come a long way in recent years.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

FEBRUARY 21, 2022

In the area of cardiovascular disease, Bayer is delivering on its late-stage pipeline including recent launches of Kerendia™ (finerenone) and Verquvo™ (vericiguat). “We Our scientific leadership in the area of cardiovascular diseases advances our mission to provide better treatment options for patients in need.”.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Clinical Trials Therapies Disease 52

DrugBank

FEBRUARY 19, 2025

billion by 2030, the sector is witnessing a shift in how drugs are conceived, developed, and tested.  Historically, the target identification process has been fraught with challenges due to the sheer complexity of diseases and the large volume of data that needs to be analyzed. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

MAY 17, 2023

“Following Benin’s and Mali’s success, trachoma remains endemic in 23 countries in WHO’s African Region, bringing us a step closer towards the elimination target for trachoma set in the road map for neglected tropical diseases 2021–2030.” The disease is caused by infection with the bacterium Chlamydia trachomatis.

Disease 40

Disease International Treatment 40

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. These include.

Therapies 40

Therapies Trials Treatment Disease 40

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). Alzprotect is committed to the development of innovative therapeutic solutions in the field of neurodegenerative diseases.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

Vial

MAY 20, 2024

In the field of clinical research , this pipeline can be broken down into several stages and processes specifically designed to rigorously validate the safety and efficacy of new drugs and treatments. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

SEPTEMBER 16, 2020

We’re currently working to support global health efforts to address diseases like malaria and leprosy, to continue novel research into tropical diseases, and to ensure access to our new medicines in low- and middle-income countries,” said Vas Narasimhan, CEO of Novartis.

Therapies 52

Therapies Regulations Government Disease 52

The Pharma Data

MARCH 2, 2021

This biological solution responds to Bayer’s commitment to help reduce the environmental impact of crop protection by 30% by 2030 without reducing crop yields. The launch of Vynyty Citrus ® at this year’s SHE2021 event coincides with 2021 being designated as the International Year of Fruits and Vegetables by the United Nations.

Production 52

Production International Science Licensing 52

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Food and Drug Administration for the treatment of adult patients with chronic kidney disease and type 2 diabetes. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. MHRA launched the pilot in late 2023 and ultimately chose eight products with different technologies that address life-threatening diseases with no equivalent solutions that also support the U.K.’s s Life Sciences Vision.

Regulations 40

Regulations International Government Production 40

DrugBank

AUGUST 9, 2024

Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  This exponential growth is primarily fueled by the escalating global burden of chronic diseases. billion by 2030. trillion by 2028.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

The Pharma Data

NOVEMBER 12, 2020

Committee A, which focuses on programme and budget matters, decided to recommend the adoption of the first-ever resolution on meningitis, which would approve a global roadmap to defeat meningitis by 2030 – a disease that kills 300,000 people annually and leaves one in five of those affected with devastating long-term consequences.

Disease 52

Disease Treatment 52

The Pharma Data

MAY 26, 2023

More ways, to save more lives, for less money: World Health Assembly adopts more Best Buys to tackle noncommunicable diseases The World Health Organization has expanded the list of ‘NCD best buys’. The report is part of the NCDs Global Action Plan 2023-2030 and is an update from 2017 and is core to the Implementation Roadmap on NCDs.

Disease 52

Disease Government Treatment Production 52

The Pharma Data

MARCH 11, 2021

Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs. Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient ma. Without accurate diagnosis, appropriate disease management may be delayed.

Disease 52

Disease Treatment Laboratories Virus 52

The Pharma Data

APRIL 12, 2022

WHO welcomes the establishment of a new Heads of State and Government Group to accelerate progress towards the SDG target for noncommunicable diseases ? a one-third reduction in “premature” deaths from diseases like diabetes, cancer, heart and lung disease and the promotion of mental health and well-being.

International 52

International Disease Government Treatment 52